St George's Hospital

Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Clinical and Scientific Advisory Boards

Retrieved on: 
Tuesday, March 26, 2024
Tao, Internal medicine, Professor, Patient, Pulmonology, Executive Committee, Drug, Therapy, Chairperson, Sensation, Genentech, NSW, St George's Hospital, Harvard University, MTR, Pediatrics, Stanford University, Teaching hospital, Critical care, Outline of health sciences, KCP, Neuroinflammation, UCSF, Research, Acquisition, University, Management, MPH, Drug development, Atopic dermatitis, Entrepreneurship, Critical Care Medicine (journal), Adolescence, Contact dermatitis, Science, Division, KRYS, Pharmaceutical industry

FREMONT, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the appointment of Hubert Chen, M.D., MPH, as Chief Medical Officer, effective March 21, 2024. Dr. Chen brings extensive clinical and industry leadership experience in drug development and joins Attovia from Krystal Biotech (NASDAQ: KRYS), where he was Senior Vice President of Clinical Development. At Attovia, Dr. Chen will lead the company’s clinical development and regulatory functions and will serve on the Executive Committee.

Key Points: 
  • Dr. Chen brings extensive clinical and industry leadership experience in drug development and joins Attovia from Krystal Biotech (NASDAQ: KRYS), where he was Senior Vice President of Clinical Development.
  • At Attovia, Dr. Chen will lead the company’s clinical development and regulatory functions and will serve on the Executive Committee.
  • Prior to Krystal, Dr. Chen was at Genentech/Roche where he held clinical leadership positions across both early and late-stage development.
  • To support the ongoing strategic development of the Attobody platform and advancement of the Company’s emerging pipeline candidates, Attovia has established Clinical and Scientific Advisory Boards comprised of biopharmaceutical industry veterans and academic experts.

Velocity aggressively expands MASH/MASLD capabilities with latest site acquisitions

Retrieved on: 
Wednesday, October 25, 2023
Potsdam Institute for Climate Impact Research, Gastroenterology, FDA, Research, Oregon Health & Science University, United States Department of the Air Force, Obesity, General Social Care Council, Prevalence, Biological therapy for inflammatory bowel disease, Liver disease, Paulinum (University of Leipzig), ChromeOS, CPI, Tufts University School of Medicine, AGAF, Growth, Disease, St George's Hospital, NASH, University, KOL, Internal medicine, Icahn School of Medicine at Mount Sinai, Air force, Brooke Army Medical Center, DURHAM, FACP, FACG, Hepatology, Veteran, Patient, MASH, Dietary supplement, Pharmaceutical industry, Medical device, Nursing, MD, Velocity

DURHAM N.C., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Velocity Clinical Research (“Velocity”), the leading multi-specialty clinical sites business, announced it has acquired Impact Research Institute (Waco, TX) and the clinical trials unit of Liver Institute Northwest (Seattle, WA), aggressively expanding its capabilities in liver disease research, including MASH (metabolic dysfunction-associated steatohepatitis) and MASLD (metabolic dysfunction-associated steatotic liver disease).

Key Points: 
  • Velocity is a major player in this space with 23 sites capable of performing MASH/MASLD studies globally.
  • With the two recent site acquisitions, Velocity adds two internationally renowned researchers and key opinion leaders (KOL) in liver disease research as principal investigators, Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, and Nadege Gunn, MD, CPI, who join Roland Kuchta, MD, in Germany.
  • Dr. Gunn commented, “We are fully prepared to make Velocity the first-choice site network for liver disease clinical trials worldwide.
  • Velocity has over 80 locations globally and access to more than 220 principal investigators and one million patients.

The British Journal of Dermatology Publishes Results from Amryt’s EASE Phase 3 Trial in Epidermolysis Bullosa

Retrieved on: 
Tuesday, October 25, 2022
Royal Melbourne Hospital, Wound healing, Journal of the American Academy of Dermatology, Acceleration, Epidermolysis bullosa, Patient, JEB, University of New South Wales, NSW, Degenerative disease, University, DEB, EB, Pain, Safety, St George's Hospital, Principal, Pharmaceutical industry, Dermatology, EU, EASE

EASE is the largest Phase 3, randomised, controlled study in Epidermolysis Bullosa (EB), that examined the efficacy and safety of Filsuvez (birch bark extract) gel/Oleogel-S10 versus vehicle control gel in EB.

Key Points: 
  • EASE is the largest Phase 3, randomised, controlled study in Epidermolysis Bullosa (EB), that examined the efficacy and safety of Filsuvez (birch bark extract) gel/Oleogel-S10 versus vehicle control gel in EB.
  • *
    Key outcomes from the EASE double-blind phase included:
    Professor Dedee Murrell, Head of Dept.
  • The EASE trial (NCT03068780) is the largest ever global Phase 3 trial conducted in patients with EB, performed across 58 sites in 28 countries.
  • It comprises a 3-month double-blind randomized controlled phase followed by a 24-month open-label, single-arm phase.

Amryt Announces Positive Interim Analysis Data From Open Label Phase of EASE Phase 3 Trial in EB

Retrieved on: 
Saturday, March 26, 2022
Company, Risk, Death, EB, Degenerative disease, Epidermolysis bullosa, Body surface area, AAD, Skin, St George's Hospital, Wound healing, Patient, Stenosis, DBP, American Academy of Dermatology, Safety, EASE, American Academy, Scar, Ulcer, OLP, Esophagus, Infection, Department, Systemic disease, Pharmaceutical industry, UNSW

These data were presented during a late-breaking oral presentation at the American Academy of Dermatology (AAD) Annual Meeting 2022 held in Boston, MA.

Key Points: 
  • These data were presented during a late-breaking oral presentation at the American Academy of Dermatology (AAD) Annual Meeting 2022 held in Boston, MA.
  • Professor Dedee Murrell, M.D., added This new analysis reinforces the clinical benefit where patients had sustained improvement despite ongoing development of the systemic disease in EB.
  • The EASE trial ( NCT03068780 ) is the largest ever global Phase 3 trial conducted in patients with EB, performed across 58 sites in 28 countries.
  • Of those that completed the double-blind phase, 100% entered the open label safety follow up phase.

Parliament Fundraising Event in Aid of St George's Hospital Charity Children's Appeal

Retrieved on: 
Thursday, December 6, 2018
St George's Hospital, St George's, University of London, Tooting, Health, London

On Thursday 29 November an event was held at the Palace of Westminster in aid of St George's Hospital Charity Children's Appeal.

Key Points: 
  • On Thursday 29 November an event was held at the Palace of Westminster in aid of St George's Hospital Charity Children's Appeal.
  • The fundraising gathering was attended by both supporters of the charity and medical staff from St George's.
  • Amerjit Chohan, Chief Executive of St George's Hospital Charity, expressed appreciation that so many guests had come out to support the charity and thanked Dmitry Leus and Imperium Investments for their continued support of the charity and in making the event happen.
  • To learn more about the work of St George's Hospital Charity, please visit the website .